Form 4: Crinetics Pharmaceuticals Executive Sells Shares After Option Exercise
SEC Form 4 Filing
Dana Pizzuti, Chief Medical and Development Officer of Crinetics Pharmaceuticals, executed stock options and sold shares on October 3, 2024, according to a recent SEC filing.
Summary
- On October 3, 2024, Dana Pizzuti, the Chief Medical and Development Officer of Crinetics Pharmaceuticals, exercised stock options to acquire 14,375 shares of common stock at a price of $16.89 per share.
- Simultaneously, Pizzuti sold 14,375 shares in the open market at a weighted average price of $54.63 per share, with prices ranging from $53.53 to $55.29.
- Following these transactions, Pizzuti directly owns 28,507 shares of Crinetics Pharmaceuticals common stock and holds options for 139,042 shares.
- The sale was executed automatically under a pre-arranged Rule 10b5-1 trading plan.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to insider trading. It doesn't inherently convey positive or negative sentiment, but rather reports factual transactions.
Industry Context
Executive stock sales are a common occurrence and are often part of pre-planned diversification strategies. The use of a 10b5-1 plan suggests the transactions were planned in advance to avoid any appearance of trading on inside information.
Comparison to Industry Standards
- Executive compensation packages often include stock options as a way to align management's interests with those of shareholders.
- Rule 10b5-1 trading plans are a standard practice for corporate insiders to sell shares without raising concerns about insider trading.
- The sale price of $54.63 per share reflects the current market valuation of Crinetics Pharmaceuticals, which can be compared to its peers in the biotechnology industry.
Stakeholder Impact
- The sale of shares by a high-ranking executive could be perceived negatively by some shareholders, although the use of a 10b5-1 plan mitigates this concern.
- The transactions have no immediate impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| September 30, 2023 | 25% of the shares subject to the option vest |
| October 3, 2024 | Pizzuti exercised stock options and sold shares. |
| October 7, 2024 | Date of the signature on the Form 4 filing. |
| October 10, 2032 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.